Biogen Idec and mondoBIOTECH sign collaboration and licensing agreement to develop and commercialize Aviptadil
18-Sep-2006 -
Biogen Idec and mondoBIOTECH AG announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH).
Under terms of the agreement, ...
Biogen Idec
license agreements
Orphan Drug Designation
+2